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Abstract
Bipolar disorder (BD) is a debilitating psychiatric condition with a prevalence of 1–2% in the general population that is
characterized by severe episodic shifts in mood ranging from depressive to manic episodes. One of the most common
treatments is lithium (Li), with successful response in 30–60% of patients. Synapsin II (SYN2) is a neuronal phosphoprotein
that we have previously identified as a possible candidate gene for the etiology of BD and/or response to Li treatment in a
genome-wide linkage study focusing on BD patients characterized for excellent response to Li prophylaxis. In the present
study we investigated the role of this gene in BD, particularly as it pertains to Li treatment. We investigated the effect of
lithium treatment on the expression of SYN2 in lymphoblastoid cell lines from patients characterized as excellent Li-
responders, non-responders, as well as non-psychiatric controls. Finally, we sought to determine if Li has a cell-type-specific
effect on gene expression in neuronal-derived cell lines. In both in vitro models, we found SYN2 to be modulated by the
presence of Li. By focusing on Li-responsive BD we have identified a potential mechanism for Li response in some patients.
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Introduction
Bipolar disorder (BD) is a major topic in health research given
its debilitating nature, lifetime prevalence and significantly high
occurrence in the general population (1–2%) [1].This psychiatric
condition is characterized by abnormal shifts in energy, activity
levels, mood, and one’s ability to carry out routine tasks. In
comparison to other psychiatric conditions, BD has been shown to
have relatively high heritability, with estimates ranging from 60 to
85% [1,2]. One of the most common treatments of BD is lithium
(Li), administered as metallic salts, due to its proven efficacy both
as a short term intervention for manic episodes as well as a
prophylactic against episode recurrence. The drug has been highly
prescribed since the 1950s and 1960s when Mogens Schou showed
its efficacy through a series of systematic trials with BD patients
[3], and demonstrated a high success rate with approximately 30–
60% of patients showing full or partial treatment response [4,5].
Synapsin II (SYN2) is a gene that codes for a neuronal
phosphoprotein involved in synaptic plasticity and transmission as
well as synaptogenesis. It maps to chromosome 3p25 and has two
known variants, IIa and IIb, which are highly expressed in nerve
terminals in the majority of the adult brain [6] with demonstrated
homology across numerous vertebrate and invertebrate organisms
[7]. The majority of brain regions co-express synapsin genes at
similar levels, suggesting that they are functionally complementary
[8], and though all synapsins have been primarily studied for their
roles in the brain, the genes’ expression is widespread in the
peripheral nervous system. In non-neuronal cells, synapsins are
mostly found in association with the cytoskeleton, where their
involvement is likely at the level of vesicular trafficking [7]. For
example, Syn2 protein was isolated from rat as well as bovine
chromaffin cells of the adrenal medulla [9,10]. Though limited
work has been done on SYN2 outside of neurons, expression of
other synapsins has been shown in undifferentiated astrocytes [11],
osteoblasts [12], liver endosomes [13], epithelial cells [14], as well
as the cell lines HeLa and NIH/3T3 [15].
Given the multiple roles played by synapsins in neuronal cell
function and maintenance, it may be hypothesized that disruption
of these roles could result in the onset of pathological conditions.
Indeed, knockout experiments have shown the absence of SYN2 to
induce epileptic-like seizures in mice [16,17] and genetic mapping
identified variants in the SYN2 gene as significantly contributing
to epilepsy predisposition [17,18]. Genetic association studies have
also linked SYN2 variants with schizophrenia, as shown in affected
families of different genetic backgrounds [19,20,21]. Data for BD
are more limited, however. The only reported case-control
analysis of SYN2 single nucleotide polymorphisms (SNPs) in
individuals with BD comes from Wang et al. who studied the Han
Chinese population but did not find any significant association
[22]. Additional work has been reported for SYN2 at the protein
or mRNA levels, where several studies showed significant
dysregulation in alcoholism, Huntington’s disease, and schizo-
phrenia [23,24,25]. In BD, Vawter et al. showed differential down-
regulation of SYN2 protein levels in hippocampi of patients
compared to non-psychiatric controls. We have recently published
a linkage study in families ascertained through Li-responsive BD
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interesting candidates [26]. In the same study, at the mRNA
expression level, SYN2 was shown to be up-regulated in the
prefrontal cortex of patients [26]. In the present study, we
hypothesize that the implication of SYN2 in BD is more
prominent in a subset of BD patients. Moreover, we predict that
in such patients SYN2 is more relevant to the response to lithium
treatment.
To explore these hypotheses, we conducted a series of studies
investigating the expression of SYN2 in BD, particularly as it
pertains to lithium treatment. Because this candidate gene was
originally identified through a linkage study of lithium-responsive
BD families, we investigated what effect lithium treatment would
have on the expression of SYN2. We performed in vitro long-term
treatment studies in Epstein-Barr-virus transformed lymphoblas-
toid cell lines (LCLs) from BD patients characterized for excellent
Li-response (as described previously) [27,28,29] in order to identify
the effect of this drug in a model replicating the genetic
background of response. In addition, we performed the same
experiments with human neuroblastoma and glioblastoma cells to
model the biological context.
Materials and Methods
I. Ethics statement
Ethics approval for the use of human samples in this study
was obtained from the Capital District Health Authority
(CDHA) in Halifax, Nova Scotia. All subjects gave written
informed consent to their participation in the study in regards to
sample collection and the generation of lymphoblastoid cell
lines; no subjects had reduced capacity to consent. Sample
collection and cell lines generation has been described
previously [29,30].
II. BD Li-response lymphoblastoid samples
Subjects were diagnosed with BD I and BD II according to both
Research Diagnostic Criteria (RDC) and DSM-IV criteria, and
followed prospectively at specialized clinics in Hamilton, Ottawa
and Halifax [27]. Their clinical course was characterized by a
high number of manic and depressive episodes before Li
treatment. The responders (n=11) showed full stability on long-
term Li monotherapy. The non-responders (n=12) continued
experiencing illness episodes in spite of good compliance
documented by therapeutic blood levels. These are the same
criteria as outlined previously [27,28]. Unaffected controls
(n=13) were matched for ethnic background and excluded if
they had a history of BD, schizophrenia, or major depression.
Peripheral blood samples were obtained from patients and
controls following standard procedures and Epstein-Barr
virus-transformed b-lymphoblastoid cell lines were generated as
described previously [29,30].
III. Cell culture
To determine patient-specific effects of Li on target genes, in vitro
assays were performed in LCLs from excellent Li-responders, non-
responders, and healthy controls. Aliquots of frozen cell lines were
stored in liquid nitrogen after Epstein-Barr virus transformation for
each sample according to ‘‘LCL frozen storage’’ time until all
samples were randomized, thawed for experiments, grown and
processedina sequentialfashionas described below. This effectively
ensures no difference in passage number between LCL samples and
no batch effect. Cells were cultured in Iscove’s Modified Dulbecco’s
Medium (IMEM) supplemented with 15% FBS, 1% Fungizone and
1% penicillin/streptomycin/glutamine (Invitrogen) in a 5% CO2
humidified incubator at 37uC, in the continuous presence of
1.0 mM LiCl or vehicle (NaCl) for 7 days [29] after which cell
pellets were collected and frozen at 280uC. Experiments were
performed in triplicate. Clinical and demographic characteristics of
patient and control LCLs are listed in Table 1.
To determine cell-type-specific modulation of candidate genes
in the brain, in vitro assays were performed in three cell lines:
HEK293 (human embryonic kidney, ATCC CRL1573) as a non-
brain control, SK-N-AS (human neuroblastoma, ATCC
CRL2137), and U-118 MG (human glioblastoma; astrocytoma,
ATCC HTB15). Cells were cultured at 37uC in Dulbecco’s
Modified Eagle Medium (DMEM) supplemented with 10% FBS,
100 U/ml penicillin and 100 mg/ml streptomycin (Invitrogen) in a
5% CO2 humidified incubator at 37uC. For Li treatments, cells
were grown in the continuous presence of 0.5 mM, 1.0 mM, or
2.0 mM LiCl or vehicle (NaCl) for 7 days after which cell pellets
were collected and frozen at 280uC. Experiments were performed
in triplicate.
IV. Real-time PCR
Total RNA was extracted from frozen cell pellets using the
RNeasy Mini Kit (QIAGEN). For synthesis of cDNA, M-MLV
reverse transcriptase (Gibco, Burlington, Ontario) and oligo(dT)16
primers (Invitrogen) were used. Real-time PCR reactions were run
in quadruplicate using an ABI PRISM 7900HT Sequence
Detection System (Applied Biosystems) and the Power SYBRH
Green PCR Master Mix (Applied Biosystems). Relative expression
was calculated using the relative quantitation method (DDCt) in
the RQ Manager 1.2 software (Applied Biosystems) with GAPDH
as an endogenous control.
V. Data analysis
Test coefficients and probability distributions were calculated
using statistical software GraphPad Prism 5 and SPSS.
Table 1. Lymphoblastoid cell line sample group demographics.
Controls (C) Responders (R) Non-Responders (N) Group differences (p#0.05)
Subjects (M/F) 13 (3/10) 11 (5/6) 12 (3/9) Not Significant
Age at DNA sampling (yr) 3164.7 53.564.3 47.963.8 C vs. R and C vs. N
LCL frozen storage (yr) 3.760.3 7.861.0 6.860.5 C vs. R and C vs. N
Age at onset (yr) n/a 32.663.5 29.863.5 Not Significant
Data are presented as mean6SEM for non-psychiatric controls, bipolar disorder patients who are excellent lithium responders (‘‘Responders’’) and bipolar disorder
patients who do not respond to lithium treatment (‘‘Non-Responders’’). ‘‘Age at sampling’’ refers to the subject’s age at the time blood was drawn. ‘‘LCL frozen storage’’
refers to the length of time of liquid nitrogen storage after Epstein-Barr-Virus transformation. ‘‘Age at onset’’ refers to the age at which patients were diagnosed with BD.
doi:10.1371/journal.pone.0032680.t001
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Lithium affects gene expression in transformed
lymphoblastoid cell lines (LCLs) distinctly in lithium
responders compared to both non-responder BD
patients and controls
To determine patient-specific effects of Li on the target genes, in
vitro assays were performed in Human Epstein-Barr virus–
transformed LCLs from excellent Li-responders (R), non-respond-
ers (N) and controls without psychiatric history (C) [30]. For long-
term treatment, cells were cultured in the continuous presence of
1.0 mM treatment (LiCl) or vehicle (NaCl) for 7 days [29]. Data in
Figure 1 are presented as fold change between Li treatment and
vehicle treatment values. We performed a ANCOVA analyses
with ‘‘Age at Sampling’’ and ‘‘LCL frozen storage’’ as covariates,
followed by Tukey’s multiple comparison post-tests for group
comparisons, but found no significant mean differences between
the three groups: C vs. R, C vs. N, and R vs. N for either Synapsin
II variant (SYN2a p=0.613, SYN2b p=0.691), as shown in
Table 2.
Interestingly, there was a significant difference in the distribu-
tion of expression fold-change in the responder patient group as
compared to the non-responders and the controls. LCLs from
non-responder BD patients displayed the same distribution pattern
as the controls whereas the Li-responder patient LCLs had a
broader spectrum of expression than the other two groups. The
same pattern was observed with the SYN2a variant shown in
Figure 1.A (F-test P=0.001 for both C vs. R and N vs. R) as with
the SYN2b variant shown in Figure 1.B (F-test P,0.001 for both
C vs. R and N vs. R). Furthermore, the expression pattern was
consistent across the two variants, with subjects showing
consistently low or high expression in both the SYN2a and
SYN2b variant. This was illustrated through the color-coding in
Figure 1.
Environmental factors do not explain the variant effect of
lithium in Responders
Given the fact that in some patient LCLs both SYN2a and
SYN2b were up-regulated by lithium treatment while in others the
two variants were down-regulated, we attempted to elucidate the
stratifying factors responsible for this behavior. Ethnic background
did not differ across subjects as all were Caucasian of European
descent, so this variable was not included in the analyses. We
investigated a number of other factors including age of onset,
initial Li prescription, and time on Li prior to DNA collection
(Table 3). Furthermore, we investigated factors relating to
psychiatric medication such as Li dosage and use of other
medications, as well as family history of other psychiatric
disorders. We determined normality of each dataset using a
Shapiro-Wilk normality test and computed Pearson’s correlations
for normally distributed and Spearman’s correlations for non-
normally distributed datasets. None of the 15 potential environ-
mental covariates showed significant correlations with either
SYN2a or SYN2b expression values, demonstrating that the
reported variance difference cannot be explained by these possible
covariates (Table 3).
Synapsin II shows cell-type specific response to lithium
treatment in neuroblastoma cells
Since our previously reported brain expression results [26] were
from homogenate tissue brain extracts, we set out to investigate a
possible cell-type-specific effect of lithium treatment. As such, we
used three cell lines representing neurons (SK-N-AS), glial cells (U-
118 MG) and embryonic kidney cells as a non-central nervous
system cell control (HEK293). In order to detect concentration-
specific effects, three different concentrations of treatment (LiCl) or
vehicle (NaCl) were used: 0.5 mM, 1.0 mM, and 2.0 mM – the
values represent lower and higher ends of the therapeutic
concentrations of lithium used clinically. SYN2a demonstrated a
Figure 1. Lymphoblastoid cell line expression. Relative Quantification (RQ) values from qRT-PCR relative to GAPDH as an endogenous control.
The groups compared are non-psychiatric controls, bipolar disorder patients without positive response to lithium (Non-Resp) and bipolar disorder
patients with excellent response to lithium. The expression analyses were performed with separate primer sets for SYN2a (left) and SYN2b (right). The
asterisks refer to F-test p-values depicting the differences in distribution between the individual expression changes in each group (** p-value#0.001;
*** value#0.0001). There were no significant mean group differences, as indicated in Table 2.
doi:10.1371/journal.pone.0032680.g001
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compared to vehicle at both of the two higher treatment
concentrations: 1.0 mM and 2.0 mM (P=0.001 and 0.035,
respectively) in the neuronal cell line (Figure 2). A similar data
set was collected for the SYN2b variant, but this had no significant
change in expression in any of the conditions tested (Figure 3),
suggesting that our findings are specific to SYN2a.
Discussion
Synapsin II is a candidate gene that was originally identified
through a linkage study of Li-responsive BD families. This gene
was also shown to be dysregulated in the post-mortem brains of
patients with BD as compared to psychiatrically healthy controls in
the same study [26]. Thus, we were interested to investigate the
effect of Li treatment on the expression of this gene. We did so in
the genetic context of the disorder by treating with Li
monotherapy Epstein-Barr virus-transformed lymphoblastoid cell
lines from BD patients characterized as excellent Li-responders or
non-responders, as well as healthy controls with no history of
psychiatric disorders. We found that the pattern of expression was
significantly different in Li-responders compared to both non-
responder BD patients as well as controls. However, the direction
of change of expression was not uniform across subjects (Figure 1),
resulting in no overall mean differences between groups. These
data suggest that Li modulates SYN2 expression in a way that is
specific to Li-responders, possibly reflecting significant genetic
heterogeneity.
The relevance of SYN2 expression in peripheral cells compared
to the central nervous system in BD patients is not clear from our
findings, particularly since we saw no mean differences between
Li-responders, non-responders, and controls. It is however clear
from the literature that the gene is expressed, though at more basal
levels, in lymphoblasts as well as many other cell types. Despite
their peripheral origin, studying transformed LCLs offers the
benefit of performing in vitro assays on cells from patients and
studying putative factors in their endogenous expression context.
However, results from these experiments should be considered
Table 2. Lithium response in lymphoblastoid cell line samples.
SYN2a SYN2b
Control/Non-
Responder
Control/
Responder
Non-Responder/
Responder
Control/Non-
Responder
Control/
Responder
Non-Responder/
Responder
ANCOVA p-value 0.867 0.916
Tukey’s Test 0.231 1.315 1.112 0.108 0.993 1.123
F-test 0.897 0.001** 0.001** 0.839 0.0009*** 0.0008***
ANCOVA analysis was performed to compare the three groups (Controls, Responders, and Non-responders to lithium treatment) separately for Syn2a and Syn2b
expression. The variables ‘‘Age at sampling’’ and ‘‘LCL frozen storage’’ were used as covariates.
doi:10.1371/journal.pone.0032680.t002
Table 3. Correlations of covariates with RQ expression values in excellent lithium responders.
Shapir- Wilk Normality SYN2a RQ SYN2b RQ
p-value
Normal
distribution
Pearson
coefficient
Spearman
coefficient p-value
Pearson
coefficient
Spearman
coefficient p-value
LCL frozen storage (yr) 0.2207 Yes 0.211 0.533 0.237 0.482
Age at DNA sampling (yr) 0.8805 Yes 20.070 0.838 20.065 0.849
Age at Onset (yr) 0.6388 Yes 0.217 0.521 0.158 0.644
Age at first treatment Li (yr) 0.3542 Yes 20.404 0.320 20.449 0.264
Time between onset and DNA collection 0.2446 Yes 20.291 0.385 20.227 0.502
Li Treatment response Score 0.2172 Yes 20.129 0.705 20.185 0.585
Episodes before Li 0.0114 No 20.527 0.145 20.527 0.145
Time on Li treatment (yr) 0.0456 No 0.477 0.194 0.477 0.194
Li dose at DNA sampling 0.5553 Yes 20.437 0.239 20.432 0.246
Number of other psych drugs 0.169 Yes 0.277 0.470 0.345 0.364
Family History Depression 0.0012 No 0.015 0.965 0.015 0.965
Family History Bipolar Disorder 0.0085 No 20.193 0.569 20.193 0.569
Family History Schizophrenia
Family History Anxiety ,0.0001 No 0.100 0.770 0.100 0.770
Family History Alcoholism 0.0004 No 0.438 0.178 0.438 0.178
To try and explain the distribution abnormal of Syn2 expression in Li-responders we computed correlations between RQ values and 15 potential covariates relating to
age at sampling, onset, treatment start, etc., lithium treatment, as well as family history of other psychiatric disorders. (No samples had any family history of
schizophrenia.) Normality of distribution was determined using the Shapiro-Wilk normality test and correlations were determined using Pearson’s or Spearman’s tests
accordingly. No significant correlations were found with any of these variables.
doi:10.1371/journal.pone.0032680.t003
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this cell type is unclear.
Environmental factors could be involved in Li’s regulatory role,
which might account for the observed patient-specific effects in Li-
responders. To investigate this possibility we computed correla-
tions with a number of environmental factors relating to age of
patients, Li therapy, and family history of other psychiatric
disorders (for a complete list, refer to Table 3). However, none of
the potential covariates correlated with SYN2a or SYN2b
expression values, suggesting that the source of variation may be
related to genetic or possibly epigenetic differences between
patients. For example, variants in CREB genes [31] or GSK3B
[32], have been shown to associate with Li-treatment response.
Similarly, it is possible that epigenetic factors may increase SYN2
expression variance among patients. Though this is of interest, to
our knowledge, no studies have investigated the role of Li
treatment on epigenetic modifications in the human brain.
However, valproate, another widely used mood stabilizer, is well
known for its inhibitory effect on histone deacetylases (HDACs)
[33,34] and therefore, it is possible that at least part of Li’s action
may be related to epigenetic regulation. Another epigenetic
regulatory level where lithium’s effect could be confounded is
microRNA-mediated regulation. Studies in LCLs [35] and animal
models [36] have shown the drug’s global effect on this class of
molecules. For a variety of biological reasons, each patient’s LCLs
could be enriched in a combination of regulatory factors which
could then impact the response to Li treatment.
Since our LCL results do not automatically represent what is
occurring in the brain, we sought to determine if Li would have a
cell-type-specific effect on SYN2 expression in model cell lines
representative of the brain, and showed a significant change in the
neuronal cell line SK-N-AS only (Figures 2 and 3). There was an
effect at 1.0 and 2.0 mM Li, but not at 0.5 mM, suggesting that
this concentration was not high enough to elicit a response.
Interestingly, the effect was specific to the SYN2a variant
(Figure 2), as the SYN2b variant remained unchanged between
conditions (Figure 3). Originally, SYN2 had been believed to
display neuron-specific expression in the brain; however, further
studies demonstrated the gene’s expression in other cell types,
though at considerably lower concentrations [37,38]. SYN2 is
expressed at basal levels in various cell types and thus lithium likely
modulates its expression to a certain degree in these cells but
perhaps not in a functionally-relevant manner. This is consistent
with the fact that synapsins are evolutionarily conserved from
humans to very primitive organisms and likely their expression has
become more specialized in higher organisms through a loss of the
ability to regulate other cellular functions but not necessarily
through a complete loss of expression [7].
According to our results, in neurons, Li treatment significantly
increases SYN2 expression perhaps by also recruiting other
Figure 2. Cell lines expression for SYN2a. Expression in (A) HEK293 embryonic kidney cells, (B) SK-N-AS neuroblastoma cells, and (C) and U-118
MG glioblastoma/astrocytoma cells for the Synapsin IIa variant compared to GAPDH. P-values depicting the mean differences between 3
independent experiments for each cell line at each of the 3 treatment concentration of either lithium or vehicle (0.5 mM, 1.0 mM, and 2.0 mM).
doi:10.1371/journal.pone.0032680.g002
Figure 3. Cell lines expression for SYN2b. Expression in (A) HEK293 embryonic kidney cells, (B) SK-N-AS neuroblastoma cells, and (C) and U-118
MG glioblastoma/astrocytoma cells for the Synapsin IIb variant compared to GAPDH. P-values depicting the mean differences between 3
independent experiments for each cell line at each of the 3 treatment concentration of either lithium or vehicle (0.5 mM, 1.0 mM, and 2.0 mM).
doi:10.1371/journal.pone.0032680.g003
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promoter such as EGR1 (early growth response 1), which has
been suggested to regulate the gene [39], or AP-2alpha, which has
been shown to be regulated by lithium [40]. Our results from
LCLs are seemingly contradictory, as Li has an up-regulating
effect on SYN2 in some patients, and a down-regulating effect in
others. To interpret these results, one needs to consider that
lithium acts as a mood stabilizer in patients who present both
manic and depressive episodes. These clinical episodes are
characterized by symptoms that are on opposite sides of the
mood spectrum. Accordingly, manic patients present mood and
neurovegetative activation, while depressed patients are charac-
terized by a decreased mood levels and neurovegetative inhibition.
Therefore, in order to be an effective mood stabilizer, Li needs to
act by normalizing variance.
One interesting addition to this study would have been direct
evidence for the effect of Li on SYN2 expression in the central
nervous system of BD patients. An ideal study would investigate
the expression of SYN2 variants in the post-mortem brains of BD
patients who had been excellent responders to prophylactic Li for
an extended period of time, so as to match the criteria used for our
LCL samples. However, post-mortem brain donors with a history
of BD are most often suicide completers. The literature provides
extensive evidence for the anti-suicidal effects of Li prophylaxis
through observational studies [41,42], randomized controlled
studies [43,44] and meta-analyses [45,46]. Thus, such a study
would be logistically quite challenging.
Another limitation of our study is the lack of protein-level
evidence to support our mRNA-level findings. Such validation
would be interesting in the pursuit of qualifying SYN2 as a factor
of potential pharmacological significance. However, the results
presented here mainly point to SYN2 as a new mediator of Li
action. Perhaps by further investigating how SYN2 is regulated we
will also elucidate lithium’s mode of action. There are likely several
regulatory levels at play and clarifying them will be instrumental
for our understanding of lithium response in BD, but as it stands
the pharmacological application of this work is preliminary.
In conclusion, this is, to our knowledge, the first study
attempting to determine the effect of Li treatment on mRNA-
level expression of SYN2. We found a responder-specific effect of
Li in LCLs from BD patients, suggesting that even though the
gene is important for BD in general, there are genetic or epigenetic
differences in Li responders that make them more susceptible to
modulation of SYN2. Additionally, we showed that the effect of
long-term treatment with Li is likely cell-type specific. As far as
brain expression, our data suggest that the effect of lithium
treatment is only significant in neuronal cells and not in astrocytic
or glial cells. Support from additional cell types would be
important to strengthen the validity of these conclusions. Our
distinct findings for the two SYN2 variants as well as the reported
homology in sequence and function of the family of synapsin genes
opens up the question of whether the other synapsins have a
neuron-specific effect, as well as a patient-specific effect. Our study
points to a very interesting player in response to Li prophylaxis,
but more studies are required to decipher the full pathway of Li
action that leads to its stabilizing effect in a large fraction of BD
patients.
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